...
首页> 外文期刊>The journal of sexual medicine >Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life.
【24h】

Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life.

机译:戊酸四阶段雌二醇和地诺孕(E2V / DNG)口服避孕药对性生活质量的影响的初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: A new oral contraceptive containing the natural estrogen estradiol and a 19-nortestosterone derivate dienogest (DNG) in a four-phasic 28-day regimen may be used by women. AIM: To investigate the quality of sexual life of healthy women on estradiol valerate and DNG (E2V/DNG) oral contraceptive. METHODS: Fifty-seven women (age range 18-48 years) were enrolled. The Short Form-36 (SF-36) questionnaire to assess quality of life (QoL) was administered at baseline and at the 26th day of both the 3rd and 6th cycles of oral contraceptive (OC) intake. The Short Personal Experience Questionnaire (SPEQ) to measure the change of sexual behavior was used at the 2nd, 7th, 14th, 21st, 26th, and 28th days of the baseline cycle, as well as at the same days of both the 3rd and 6th cycle of contraceptive intake. MAIN OUTCOME MEASURE: The SF-36 and the SPEQ questionnaires. RESULTS: Women reported QoL improvement at the 3rd (P < 0.05) and at the 6th cycles (P < 0.01). By SPEQ, improvement of sexuality during the 3rd and the 6th cycle with respect to baseline experience was observed (P < 0.05). The frequency of sexual activity remained basically unchanged (P = NS). Enjoyment and desire improved at the 6th cycle with respect to the 3rd cycle (P < 0.05). All women reported decreased dyspareunia at the 3rd and 6th cycles (P < 0.05). Interestingly, desire, arousal, orgasm, enjoyment, and sexual activity improved, reaching a peak around the 14th day of the menstrual cycle (P < 0.05). At the 3rd and 6th cycle, women on OCs were sexually cyclic, but the peak improvement of desire, arousal, orgasm, enjoyment, and sexual activity appeared around the 7th day of OC intake (P < 0.05). CONCLUSION: Reduced hormone-free interval is a new concept in low-dose OC regimens. Moreover, the E2V/DNG multiphasic extended regimen has been found to positively modify the sexuality of users.
机译:简介:女性可以在四阶段的28天疗程中使用一种新的口服避孕药,其中含有天然雌激素雌二醇和19-去甲睾酮衍生的二烯雌酚(DNG)。目的:研究戊酸雌二醇和DNG(E2V / DNG)口服避孕药对健康女性的性生活质量。方法:纳入57名女性(年龄在18-48岁之间)。在基线和口服避孕药(OC)摄入的第3和第6周期的第26天和第26天,进行了评估生活质量(QoL)的Short-36(SF-36)问卷。在基线周期的第2、7、14、21、26和28天以及第3和6天的同一天使用了简短的个人经历调查表(SPEQ)来测量性行为的变化避孕药的摄取周期。主要观察指标:SF-36和SPEQ问卷。结果:妇女报告在第3个周期(P <0.05)和第6个周期(P <0.01)的QoL改善。通过SPEQ,观察到在第3和第6周期相对于基线经验,性能力得到改善(P <0.05)。性活动的频率基本保持不变(P = NS)。与第六个周期相比,第六个周期的享乐和欲望得到了改善(P <0.05)。所有妇女均报告在第3和第6周期的性交困难减少(P <0.05)。有趣的是,欲望,唤醒,性高潮,娱乐和性活动得到改善,在月经周期的第14天达到峰值(P <0.05)。在第3和第6周期,服用OC的妇女具有性周期性,但在摄入OC的第7天左右,性欲,唤醒,性高潮,娱乐和性活动的高峰出现了(P <0.05)。结论:减少无激素间隔是低剂量OC方案中的一个新概念。此外,已发现E2V / DNG多阶段扩展方案可以积极地改变用户的性行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号